AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01827553 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy, 28 x 1.8 Gy
Description: Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
Study NCT01898793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
Study NCT01002209 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham HBO
Description: HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included.
Study NCT03787316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: 4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
Study NCT05281250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Description: A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
Study NCT01813565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/chondroitin sulfate
Description: Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Study NCT01827553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy, gemcitabine
Description: 5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
Study NCT01827553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
Description: Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
Study NCT04749173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 96mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study NCT01813565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid/chondroitin sulfate
Description: Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Study NCT05731934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX301
Description: At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
Study NCT03330535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders once a week
Description: Participants in this group will receive active oral hygiene reminders through text messaging once a week.
Study NCT03330535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal oral hygiene instructions
Description: Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
Study NCT03330535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders three times a week
Description: Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
Study NCT03330535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily reminders
Description: Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
Study NCT02610868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYOBLOC
Description: After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
Study NCT03940209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic needs navigation
Description: Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
Study NCT01651572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)
Study NCT01651572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)
Study NCT03146650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03146650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03146650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04047290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 is a PD1/VEGF bispecific antibody.
Study NCT00682019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 8 hours before sexual intercourse
Study NCT00682019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT03215212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask
Description: eye mask administered from 10 pm to 7 am
Study NCT03215212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocean sound
Description: Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
Study NCT01684384 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Respiratory Imaging
Description: HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
Study NCT04749173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 432mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study NCT04749173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 144mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study NCT03215212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear plug
Description: ear plug administered from 10 pm to 7 am
Study NCT02962076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)
Description: this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
Study NCT01748851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: capecitabine 1000mg/m2 bid po D1-D14
Study NCT01900470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Goal Support
Description: IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
Study NCT03653637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Life Force
Description: A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
Study NCT03653637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
Study NCT01708694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amylose
Description: One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
Study NCT01708694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amylopectin
Description: The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months.
Study NCT02036034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forced air warmer (Bair Hugger)
Description: forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
Study NCT02036034 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: warming blanket
Description: warming blanket placed on torso of patient under the drape.
Study NCT00236938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer and stable erythropoietin (EPO) regimen
Description: Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
Study NCT00236938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stable erythropoietin (EPO) regimen
Description: Stable erythropoietin (EPO) dose and no supplemental iron.
Study NCT01270945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CV-18C3
Description: 3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
Study NCT01270945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Study NCT01270945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT04652128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
Study NCT04652128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive a single infusion of physiological saline 100mL intravenously.
Study NCT02986204 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: removal of ENG implant
Description: the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined
Study NCT02986204 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: continuation of ING implant
Description: the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm
Study NCT01218997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
Study NCT01218997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral naltrexone 50 mg
Description: Tablet taken orally once daily for up to 1 year
Study NCT04139590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panda
Study NCT04139590 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Visual Analogue Scale - Original
Study NCT01752140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10-core prostate biopsy protocol
Description: Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
Study NCT01752140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vienna nomogram prostate biopsy protocol
Description: Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
Study NCT03819231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
Study NCT03819231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
Study NCT03819231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
Study NCT03819231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
Study NCT03819231 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution
Description: A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
Study NCT03819231 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham mindfulness
Description: The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
Study NCT01902485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of Contraceptive Initiation in Medical Abortion
Study NCT02505126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
Study NCT02505126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tDCS
Description: One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
Study NCT01500148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)
Description: A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
Study NCT01731704 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiosurgery (SRS)
Study NCT01212926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echographic analysis of myocardial deformation in 2D strain
Study NCT01731704 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation therapy (WBRT)
Description: External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
Study NCT06045377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia
Description: A prospective single center cohort study
Study NCT01748851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: 5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
Study NCT02400398 — intervention group
Intervention type: OTHER
Intervention: Tube feeding
Description: Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
Study NCT04341727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: anti-rheumatic drug (DMARD)
Study NCT04341727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Antibiotic
Study NCT04341727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Sulfate
Description: Antimalarial
Study NCT01103076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyamide HD membrane
Description: Single use polyamide membrane
Study NCT02418819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 3mg BID
Description: PF-06412562
Study NCT02418819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 9mg BID
Description: PF-06412562
Study NCT02418819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 45mg BID
Description: PF-06412562
Study NCT02418819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04095000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACE-TC SP
Description: The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
Study NCT04095000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
Study NCT01611324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%
Description: 4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
Study NCT01611324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%
Description: 4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
Study NCT02089750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthotics